Takeda Pairs Up With BridGene to Solve "Undruggable" Neurodegenerative Diseases
BioSpace
MARCH 29, 2021
The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.
Let's personalize your content